Michael Argenziano

Presbyterian Hospital, Columbia University

Papers

19

Total Citations

1,289

H-Index

13

About

Michael Argenziano is a pioneering cardiothoracic surgeon whose career has been defined by a relentless pursuit of minimally invasive and robotic surgical techniques. Working at the forefront of a transformative era in cardiac surgery, Argenziano has made landmark contributions to robotic mitral valve repair, totally endoscopic coronary artery bypass grafting, and atrial septal defect repair — the latter representing one of the first U.S. applications of robotic technology for intracardiac procedures. His 2005 multicenter trial on robotic mitral valve surgery (269 citations) and his prospective multicenter TECAB trial (224 citations) established critical clinical evidence for the safety and feasibility of robotic cardiac procedures at a national scale. Beyond technical innovation, Argenziano has addressed real-world concerns about adoption, including demonstrating that robotic techniques can improve patient quality of life and thoughtfully analyzing their cost-effectiveness compared to conventional surgery. His 2011 perspective on the golden age of minimally invasive cardiothoracic surgery (155 citations) reflects his broader influence in shaping the field's trajectory. With over 1,200 combined citations across his most impactful work, Argenziano remains a defining voice in the evolution of modern cardiac surgery.

Research Focus

Key Achievements

13
H-Index
19
Papers
1,289
Total Citations
68
Avg Citations/Paper
🏆 Most Cited Paper
Robotic mitral valve surgery: A United States multicenter trial
269 citations · 2005
📈 Most Prolific Year: 2003 (9 Papers)
🤝 Key Collaborators: 60
🏛 Institutions: Presbyterian Hospital, Columbia University

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago